Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.

Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, Lee JH, Lee CT.

Respir Med. 2014 Feb;108(2):388-94. doi: 10.1016/j.rmed.2013.11.020. Epub 2013 Dec 10.

PMID:
24361161
[PubMed - indexed for MEDLINE]
2.

EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.

J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.

PMID:
22124476
[PubMed - indexed for MEDLINE]
3.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

PMID:
19667264
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.

Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, Duan J, Yang L, Wu M, Wang S, Wang Y, Wu Y, Wang J.

Oncology. 2012;83(5):248-56. doi: 10.1159/000341381. Epub 2012 Sep 4.

PMID:
22964709
[PubMed - indexed for MEDLINE]
5.

Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.

Shaozhang Z, Xiaomei L, Aiping Z, Jianbo H, Xiangqun S, Qitao Y.

Genes Chromosomes Cancer. 2012 Oct;51(10):925-32. doi: 10.1002/gcc.21976. Epub 2012 Jun 27.

PMID:
22736493
[PubMed - indexed for MEDLINE]
6.

Histologic and molecular characterization of lung cancer with tissue obtained by electromagnetic navigation bronchoscopy.

Ha D, Choi H, Almeida FA, Arrossi A, Brainard J, Cicenia J, Farver C, Gildea T, Machuzak MS, Mazzone P.

J Bronchology Interv Pulmonol. 2013 Jan;20(1):10-5. doi: 10.1097/LBR.0b013e31828197e9.

PMID:
23328135
[PubMed - indexed for MEDLINE]
7.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, Zhu M, Zhang X, Wu YL.

Mol Cancer. 2010 Jul 13;9:188. doi: 10.1186/1476-4598-9-188.

PMID:
20624322
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.

Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E.

J Thorac Oncol. 2011 Jan;6(1):21-7. doi: 10.1097/JTO.0b013e3181fb7cd6.

PMID:
21107285
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.

Kanaji N, Bandoh S, Ishii T, Tadokoro A, Watanabe N, Takahama T, Haba R, Imataki O, Dobashi H, Matsunaga T.

Lung Cancer. 2012 Aug;77(2):293-8. doi: 10.1016/j.lungcan.2012.03.018. Epub 2012 Apr 10.

PMID:
22494566
[PubMed - indexed for MEDLINE]
10.

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J.

PLoS One. 2013;8(1):e52093. doi: 10.1371/journal.pone.0052093. Epub 2013 Jan 14.

PMID:
23341890
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.

Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.

BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262.

PMID:
23714228
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.

J Thorac Oncol. 2014 Feb;9(2):248-53. doi: 10.1097/JTO.0000000000000050.

PMID:
24419423
[PubMed - indexed for MEDLINE]
13.

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Tanaka H, Hayashi A, Morimoto T, Taima K, Tanaka Y, Shimada M, Kurose A, Takanashi S, Okumura K.

BMC Cancer. 2012 Nov 26;12:558. doi: 10.1186/1471-2407-12-558.

PMID:
23181703
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].

Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Chinese.

PMID:
23157740
[PubMed - indexed for MEDLINE]
15.

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.

Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP.

Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.

PMID:
23919423
[PubMed - indexed for MEDLINE]
16.

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y.

Mod Pathol. 2009 Apr;22(4):508-15. doi: 10.1038/modpathol.2009.2. Epub 2009 Feb 20.

PMID:
19234440
[PubMed - indexed for MEDLINE]
Free Article
17.

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.

Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara DR.

J Thorac Oncol. 2014 Jan;9(1):18-25. doi: 10.1097/JTO.0000000000000030.

PMID:
24346090
[PubMed - indexed for MEDLINE]
18.

Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.

Hayashi H, Okamoto I, Kimura H, Sakai K, Nishimura Y, Nishio K, Nakagawa K.

Anticancer Res. 2012 Oct;32(10):4533-7.

PMID:
23060582
[PubMed - indexed for MEDLINE]
19.

ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.

Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Iizasa T, Matsui Y, Yoshino M, Shingyoji M, Itakura M, Itami M, Ikebe D, Yokoi S, Kageyama H, Ohira M, Nakagawara A.

Lung Cancer. 2012 Jan;75(1):66-72. doi: 10.1016/j.lungcan.2011.05.027. Epub 2011 Jul 14.

PMID:
21757253
[PubMed - indexed for MEDLINE]
20.

Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.

Kobayashi M, Sakakibara T, Inoue A, Fukuhara T, Sasano H, Ichinose M, Nukiwa T.

Respir Investig. 2014 Jan;52(1):49-56. doi: 10.1016/j.resinv.2013.06.003. Epub 2013 Aug 1.

PMID:
24388371
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk